Showing 5,809 results

Filters Content type: News, Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Adherence

Tenofovir Detected in Urine Predicts HIV Viral Rebound, Drug Resistance

Editor's pick
Infectious Disease Advisor
9 November 2022
Weight gain & lipodystrophy

Obesity Risk Higher With DTG Than Other Regimens in 3 Big African Trials

Editor's pick
NATAP
1 November 2022
Pharmaceutical industry

Long-suffering CytoDyn withdraws HIV approval application for leronlimab, blaming clinical research organization

Editor's pick
FierceBiotech
1 November 2022
Injectable & long-acting HIV treatment

Who is at risk of injectable treatment failure?

News
1 November 2022
Injectable & long-acting HIV treatment

‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months

News
1 November 2022
Treatment outcomes & life expectancy

Survival prospects for older people with HIV plotted accurately by simple scoring system

News
1 November 2022
Starting treatment

After viral rebound, dolutegravir-based treatment more likely to suppress HIV

News
31 October 2022
Adherence

Do questionnaires, pill counts, or gadgets tell health staff if people with HIV are taking their drugs?

Editor's pick
Liverpool School of Tropical Medicine
31 October 2022
Ageing & HIV

Metabolic complications of newer HIV drugs in older people

Editor's pick
i-Base
31 October 2022
Antibody-based treatment

GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes long-acting combo trial

Editor's pick
FierceBiotech
28 October 2022
Side effects

CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention

News
27 October 2022
Starting treatment

Long-Term Results Confirm Benefits of Early HIV Treatment

Editor's pick
POZ
26 October 2022
Antibody-based treatment

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Editor's pick
ViiV press release
26 October 2022
People with limited treatment options

Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience

Editor's pick
NATAP
26 October 2022
Resistance

Low-level HIV and viral load blips are important warning signals, European study finds

News
19 October 2022
The search for a cure

Danish-led study takes major step in pursuit of HIV cure

Editor's pick
EurekAlert
18 October 2022
Treatment for women

Standard Integrase Regimens Have Minimal Glucose Impact in Older Black Women

Editor's pick
NATAP
14 October 2022
New & experimental HIV treatments

The paediatric drug pipeline should include improvements to current HIV treatment, long-acting formulations and antibodies

News
13 October 2022
Weight gain & lipodystrophy

Dolutegravir has direct effects on fat cells

News
12 October 2022
Ageing & HIV

Biktarvy Could Be Long-Term Option for Older Adults With HIV

Editor's pick
Infectious Disease Special Edition
6 October 2022
Resistance

Are people with a shorter history of viral suppression at greater risk of failure of dolutegravir/lamivudine?

News
6 October 2022
PrEP science

For Patients Taking PrEP, Poor Adherence Drives HIV Seroconversions

Editor's pick
Physician's Weekly
5 October 2022
People with limited treatment options

FDA Approves Trogarzo for 30-Second IV Push, Simplifying HIV Treatment for Heavily Treatment-Experienced People

Editor's pick
Infectious Disease Special Edition
5 October 2022
Drug interactions & pharmacokinetics

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Editor's pick
i-Base
3 October 2022